Congress Moves Promptly to Finalize FDA User Fees - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Congress Moves Promptly to Finalize FDA User Fees


ePT--the Electronic Newsletter of Pharmaceutical Technology

House and Senate leaders announced final agreement June 18, 2012, on legislation that authorizes industry user fees to support FDA regulatory programs. The FDA Safety and Innovation Act (S. 3187) reauthorizes the Prescription Drug User Fee Act, renews user fees for medical devices, and establishes new fees for oversight of generic drugs and for future biosimilar therapies.

FDASIA reflects agreement on the need to spur development of new antibiotics and treatments for rare conditions. It includes a number of provisions sought by FDA to better secure the pharmaceutical supply chain, to block import of adulterated products, and to detect and prevent drug shortages. The legislators, however, failed to agree on a national track-and-trace system for ensuring the integrity of drugs moving through the distribution system. Continued disagreement among wholesalers, manufacturers, and pharmacies now opens the way for the states to craft diverse drug pedigree requirements and for FDA to propose national standards where appropriate.

Several other contentious issues were dropped from the final bill. Generic-drug makers lost out on an effort to prevent brand manufacturers from using Risk Evaluation and Mitigation Strategies to block access to innovator products needed to test and develop generic versions of drugs and biologics. And pharmacists scuttled a move to stiffen controls on hydrocodone-combination painkillers, proposed as a way to curb rampant abuse of prescription drugs.

More than $6 billion in user fees will roll in over the next five years to support FDA activity.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here